Biomarker-Driven Decisions in mNSCLC

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

Access on-demand videos here: https://www.pharmacytimes.org/pages/nsclc-resource-center-moqc

The landscape of non-small cell lung cancer (NSCLC) management has moved beyond traditional chemotherapy to a precision medicine approach centered on identifying targetable driver mutations through comprehensive biomarker testing. Characterizing molecular biomarkers is the cornerstone of care in NSCLC because the identification of these alterations guides the selection of targeted therapies, which have been associated with improved patient survival. However, the current treatment paradigm is complicated by the expanding number of recommended biomarkers (now over 12), the different testing modalities, and the need for careful treatment sequencing to optimally integrate targeted agents with immunotherapy. Clinical teams must be prepared to resolve these ongoing challenges, as real-world data indicate that disparities in testing rates persist and not all patients receive the full benefit of comprehensive testing for recommended biomarkers prior to initial treatment selection. This 4-part panel discussion is designed to equip oncology teams with knowledge on current guideline recommendations for biomarker testing. Panelists will review the clinical rationale for various testing platforms and discuss strategies to address barriers to timely and complete testing. By understanding the importance of comprehensive biomarker testing and appropriate treatment sequencing, participants will be better positioned to enhance the quality of care for patients with NSCLC.

All healthcare team members are welcome to attend these free education sessions.

Please share widely with your practice. This information may be especially beneficial to APPs, nurses, pharmacists, and physicians.

If you have any questions, please reach out to Shayna Weiner (shaynaw@med.umich.edu).